New Jersey S4322 mandates healthcare platforms to consult with consumers about drugs, biologicals, and devices.
New Jersey S4322 requires healthcare platforms to advise and consult with consumers regarding the therapeutic values, content, hazards, and uses of drugs, biologicals, and devices sent to them. This consultation can occur through electronic means, including email, text messaging, and video calls. The bill supplements existing pharmacy practice laws, ensuring that healthcare platforms adhere to these standards when interacting with consumers.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.